Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–4 of 4 stories
A systematic review highlights the comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis. The findings suggest greater transplant-free survival with obeticholic acid in clinical trials compared to real-world controls.
Read full storyA recent publication discusses the ethical considerations surrounding the use of unlicensed therapies in treating primary biliary cholangitis. The article presents a counter view on the implications of such practices in clinical settings.
A recent publication addresses the ethical considerations surrounding the use of unlicensed therapies in primary biliary cholangitis. This counter view contributes to the ongoing debate about treatment options for this rare liver disease.
Recent research highlights the efficacy of seladelpar in treating primary biliary cholangitis through selective PPAR δ activation. This study may pave the way for further applications of seladelpar in related conditions.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.